Study of tofacitinib plus imatinib for palmoplantar pustulosis
Treatments studied
Part of Skin clinical trials.
This trial tests whether combining two medications, tofacitinib and imatinib, can help treat moderate-to-severe palmoplantar pustulosis (PPP). PPP causes painful pustules on the palms and soles. This study is for people whose PPP is active and has not improved significantly on its own.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with palmoplantar pustulosis for at least 12 weeks.
- Your PPP is moderate to severe, with at least 12 points on the PPPASI scale and a score of 3 or higher on the PPP-IGA.
- You have visible pustules on your palms or soles at the screening and baseline visits.
- You have not used certain biologics (IL-17 or IL-23 inhibitors) in the past, and have no active infections, cancer, or other serious medical conditions.
- You are not pregnant or breastfeeding, and you agree to avoid live vaccines during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new oral medication, ivarmacitinib, for adults with palmoplantar pustulosis (PPP) who haven't gotten better with standard treatments. It aims to see if the drug is safe and effective for reducing the painful pustules on the palms and soles.
This study tests a new drug (Xeligekimab) for people with moderate to severe palmoplantar pustulosis — a condition causing painful blisters on the hands and feet. It may be an option if other treatments haven't worked well.
This trial tests a new oral medicine (HS-10374) for people with active psoriatic arthritis who have not responded well to standard treatments. It compares the drug to a placebo to see if it reduces joint pain, swelling, and skin symptoms.
This trial tests combining two oral medications, iguratimod and tofacitinib (Xeljanz), to see if they work better together for rheumatoid arthritis that is not well controlled on current treatment.
This trial tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis (PPP), a skin condition with pustules on the palms and soles. The cream is applied daily for 16 weeks to see if it improves symptoms and is safe.
This trial tests a drug called bimekizumab for people with palmoplantar pustulosis (PPP), a skin condition causing painful pustules on the palms and soles. The goal is to see if the drug can clear these pustules and improve symptoms.
Hear when a new Palmoplantar Pustulosis (PPP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.